A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas.

Trial Profile

A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Temozolomide (Primary) ; Antineoplastics
  • Indications Astrocytoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 May 2013 Planned end date changed from 1 Oct 2012 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 03 Aug 2012 Planned end date changed from 1 Oct 2009 to 1 Oct 2012 as reported by ClinicalTrials.gov.
    • 20 May 2009 Planned end date changed from 1 Sep 2007 to 1 Oct 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top